These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 20860906)

  • 1. Incidence and clinical course of lercanidipine-associated cloudy effluent in continuous ambulatory peritoneal dialysis.
    Hsiao PJ; Lin HW; Sung CC; Wang CW; Chu P; Lin SH
    Clin Nephrol; 2010 Sep; 74(3):217-22. PubMed ID: 20860906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of carvedilol and lercanidipine on ultrafiltration and solute transport in CAPD patients.
    Topal C; Erkoc R; Sayarlioglu H; Dogan E; Beyenik H
    Ren Fail; 2009; 31(6):446-51. PubMed ID: 20187715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dihydropyridine type calcium channel blocker-induced turbid dialysate in patients undergoing peritoneal dialysis.
    Yoshimoto K; Saima S; Nakamura Y; Nakayama M; Kubo H; Kawaguchi Y; Nishitani H; Nakamura Y; Yasui A; Yokoyama K; Kuriyama S; Shirai D; Kugiyama A; Hayano K; Fukui H; Horigome I; Amagasaki Y; Tsubakihara Y; Kamekawa T; Ando R; Tomura S; Okamoto R; Miwa S; Koyama T; Echizen H
    Clin Nephrol; 1998 Aug; 50(2):90-3. PubMed ID: 9725779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cloudy dialysate due to lercanidipine.
    Topal C; Sayarlioglu H; Dogan E; Erkoc R; Soyoral Y
    Nephrol Dial Transplant; 2006 Oct; 21(10):2997-8. PubMed ID: 16735387
    [No Abstract]   [Full Text] [Related]  

  • 5. [Peritoneal dialysis-related eosinophilic peritonitis: a case report and literature review].
    Tsai SM; Yan Y; Zhao HP; Wu B; Zuo L; Wang M
    Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Aug; 50(4):747-751. PubMed ID: 30122784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Icodextrin improve angiogenesis of peritoneal membrane in continuous ambulatory peritoneal dialysis patients].
    Dai HL; Lin AW; Qian JQ; Fang W; Ni ZH; Cao LO; Lin XH; Wu QW
    Zhonghua Yi Xue Za Zhi; 2010 Nov; 90(40):2843-7. PubMed ID: 21162796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A drug-induced turbid peritoneal dialysate in five patients treated with continuous ambulatory peritoneal dialysis.
    Yoshimoto K; Saima S; Echizen H; Nakamura Y; Ishizaki T
    Clin Nephrol; 1993 Aug; 40(2):114-7. PubMed ID: 8222367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lercanidipine-induced chyloperitoneum in patients on peritoneal dialysis.
    Yang WS; Huang JW; Chen HW; Tsai TJ; Wu KD
    Perit Dial Int; 2008; 28(6):632-6. PubMed ID: 18981394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Possible role of Lercanidipine in Chiloperitoneum occurrence in CAPD: a case-report].
    Nicotera R; Chiarella S; Placida G; De Paola L; D'Onofrio G; Panzino MT; Panzino A; Mileti S; Pinciaroli AR; Coppolino G
    G Ital Nefrol; 2018 Jul; 35(4):. PubMed ID: 30035445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultrafiltration with icodextrins in continuous ambulatory peritoneal dialysis and automated peritoneal dialysis.
    Neri L; Viglino G; Cappelletti A; Gandolfo C; Cavalli PL
    Adv Perit Dial; 2000; 16():174-6. PubMed ID: 11045287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
    Nishina M; Endoh M; Suzuki D; Tanabe R; Endoh H; Hirahara I; Sakai H
    Clin Exp Nephrol; 2004 Dec; 8(4):339-43. PubMed ID: 15619033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-infectious cloudy peritoneal fluid secondary to lercanidipine.
    Moreiras-Plaza M; Fernández-Fleming F; Martín-Báez I; Blanco-García R; Beato-Coo L
    Nefrologia; 2014; 34(5):683-5. PubMed ID: 25259826
    [No Abstract]   [Full Text] [Related]  

  • 13. Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis patients.
    Vychytil A; Födinger M; Papagiannopoulos M; Wölfl G; Hörl WH; Sunder-Plassmann G
    Kidney Int; 1999 May; 55(5):2054-61. PubMed ID: 10231471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific characteristics of peritoneal leucocyte populations during sterile peritonitis associated with icodextrin CAPD fluids.
    Glorieux G; Lameire N; Van Biesen W; Dequidt C; Vanholder R
    Nephrol Dial Transplant; 2003 Aug; 18(8):1648-53. PubMed ID: 12897108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Relationship between peritoneal equilibration test and surface tension of peritoneal effluent in CAPD patients].
    Majdan M; Jeleniewicz R; Krzyzanowska E; Majdan M
    Pol Arch Med Wewn; 2004 Jul; 112(1):805-9. PubMed ID: 15526840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peritoneal sodium mass removal in continuous ambulatory peritoneal dialysis and automated peritoneal dialysis: influence on blood pressure control.
    Ortega O; Gallar P; Carreño A; Gutierrez M; Rodriguez I; Oliet A; Vigil A; Gimenez E
    Am J Nephrol; 2001; 21(3):189-93. PubMed ID: 11423687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Splenic infarction: an unrecognized cause of culture-negative peritonitis in a continuous ambulatory peritoneal dialysis patient.
    Yang CC; Lin SH; Tzeng YH; Chen CA; Tsai SH
    Clin Nephrol; 2007 Oct; 68(4):262-5. PubMed ID: 17969497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chyloperitoneum in Peritoneal Dialysis Secondary to Calcium Channel Blocker Use: Case Series and Literature Review.
    Piscitani L; Reboldi G; Venanzi A; Timio F; D'Ostilio A; Sirolli V; Bonomini M
    J Clin Med; 2023 Mar; 12(5):. PubMed ID: 36902718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of amino acid based dialysate on peritoneal blood flow and permeability in stable CAPD patients: a potential role for nitric oxide?
    Douma CE; de Waart DR; Struijk DG; Krediet RT
    Clin Nephrol; 1996 May; 45(5):295-302. PubMed ID: 8738660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
    Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R
    Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.